EGFR and neoplasm: The analysis of EGFR mutation in tissue and plasma from the AURA3 trial reported that the detection of plasma T790M was related to a larger baseline tumor size, and PFS after osimertinib (median, 12.5 vs. 8.3 months) was longer in patients with a cobas plasma T790M-negative status at pretreatment compared to those with a plasma T790M-positive status15.